MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Schrodinger Inc

Gesloten

SectorGezondheidszorg

21.62 1.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.39

Max

22.11

Belangrijke statistieken

By Trading Economics

Inkomsten

-20M

-60M

Verkoop

-29M

60M

EPS

-0.64

Winstmarge

-100.432

Werknemers

891

EBITDA

-32M

-51M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+43.56% upside

Dividenden

By Dow Jones

Volgende Winsten

30 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-260M

1.5B

Vorige openingsprijs

20.26

Vorige sluitingsprijs

21.62

Nieuwssentiment

By Acuity

59%

41%

327 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Schrodinger Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 nov 2024, 11:55 UTC

Top Nieuws

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Peer Vergelijking

Prijswijziging

Schrodinger Inc Prognose

Koersdoel

By TipRanks

43.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30.75 USD  43.56%

Hoogste 39 USD

Laagste 24 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Schrodinger Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

7

Buy

3

Hold

0

Sell

Technische score

By Trading Central

23.27 / 26.13Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Very Strong Bullish Evidence

Sentiment

By Acuity

327 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.